The Risk of Developing Osteosarcoma After Teriparatide Use: A Systematic Review.
bone tumor
malignancy
osteoporosis
recombinant parathyroid hormone
Journal
Orthopedic research and reviews
ISSN: 1179-1462
Titre abrégé: Orthop Res Rev
Pays: New Zealand
ID NLM: 101531415
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
02
2023
accepted:
13
09
2023
medline:
4
10
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
Teriparatide is a recombinant human parathyroid hormone analog with anabolic mechanism of action utilized in the treatment of osteoporosis with well-established clinical efficacy. Its use is significantly hindered due to label warnings resulting from pre-clinical rat studies demonstrating an increased risk of osteosarcoma. However, clinical trials and post-marketing surveillance studies did not demonstrate any increased risk of osteosarcoma, even after prolonged periods of surveillance reaching up to 15 years, with most of the identified cases of osteosarcomas being solitary and predominantly attributed to other factors. This systematic review provides a comprehensive overview of the currently available literature and provides the highest level of clinical evidence towards demonstrating the lack of any substantial evidence towards osteosarcoma development in patients utilizing TPTD.
Identifiants
pubmed: 37791038
doi: 10.2147/ORR.S408718
pii: 408718
pmc: PMC10544053
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
191-198Informations de copyright
© 2023 Abdulelah et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
Bone. 2018 Nov;116:58-66
pubmed: 30021126
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Int J Surg. 2019 Jun;66:1-11
pubmed: 30890377
Toxicol Pathol. 2004 Jul-Aug;32(4):426-38
pubmed: 15204966
Osteoporos Int. 2005 May;16(5):510-6
pubmed: 15322742
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1616-1626
pubmed: 32894794
J Bone Miner Res. 2012 Dec;27(12):2419-28
pubmed: 23165426
Calcif Tissue Int. 2022 Jan;110(1):74-86
pubmed: 34415388
Lancet. 2018 Jan 20;391(10117):230-240
pubmed: 29129436
Arch Intern Med. 2004 Oct 11;164(18):2024-30
pubmed: 15477438
Cancer. 2009 Apr 1;115(7):1531-43
pubmed: 19197972
Calcif Tissue Int. 2016 Sep;99(3):259-71
pubmed: 27137783
Osteoporos Int. 2011 Oct;22(10):2709-19
pubmed: 21113576
J Bone Miner Res. 2003 Jan;18(1):9-17
pubmed: 12510800
Osteoporos Int. 2021 Apr;32(4):645-651
pubmed: 33151378
JBMR Plus. 2022 Aug 14;6(9):e10665
pubmed: 36111201
Toxicol Pathol. 2002 May-Jun;30(3):312-21
pubmed: 12051548
Eur J Endocrinol. 2012 Jan;166(1):87-97
pubmed: 22048967
Osteoporos Int. 2013 Aug;24(8):2309-17
pubmed: 23404615
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Bone Miner Res. 2021 Feb;36(2):244-251
pubmed: 32990990
Clin Interv Aging. 2016 Jul 06;11:913-25
pubmed: 27462147
Calcif Tissue Int. 2018 Oct;103(4):359-371
pubmed: 29909449
Curr Med Res Opin. 2017 Nov;33(11):2049-2056
pubmed: 28699789
J Clin Endocrinol Metab. 2002 Oct;87(10):4528-35
pubmed: 12364430
Cleve Clin J Med. 2021 Sep 1;88(9):489-493
pubmed: 34470753
Osteoporos Int. 2014 Feb;25(2):639-44
pubmed: 23943162
Bone. 2021 Feb;143:115605
pubmed: 32829036